Monday, 26 Oct 2020 10:27 PM MYT
The vaccine, developed by the University of Oxford, also triggers lower adverse responses among the elderly, British drug maker AstraZeneca Plc, which is helping manufacture the vaccine, said today. “The results further build the body of evidence for the safety and immunogenicity of AZD1222,” the spokesman said, referring to the technical name of the vaccine.
The news that older people get an immune response from the vaccine is positive because the immune system weakens with age and older people are those most at risk of dying from the virus. Asked if some people could receive a vaccine this year he told the BBC: “I don’t rule that out but that is not my central expectation.”Work began on the Oxford vaccine in January. Called AZD1222 or ChAdOx1 nCoV-19, the viral vector vaccine is made from a weakened version of a common cold virus that causes infections in chimpanzees.
He said that reactogenecity, which refers to common side-effects of vaccines like soreness and redness of the arm, was “often, but not always” associated with a vaccine’s immunogenicity.
Hopingly such immunity would be lasting for years instead of short-term.
Education Education Latest News, Education Education Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: malaymail - 🏆 1. / 86 Read more »